TenAces Biosciences Business
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals
Core Technology
Artificial IntelligenceMachine LearningBiologicalsMolecules
Tags (4)
machine-learningpharmaceuticalscell-therapybiopharmaceutical
TenAces Biosciences Financials
Undisclosed
Capital raised
Cumulative Funding Raised Over Time ($)
Private Equity Funding
AION Labs, Israel Biotech Fund
TenAces Biosciences Lifecycle
Cumulative Funding Raised Over Time
All Events
AION Labs, Israel Biotech Fund
TenAces Biosciences News
1 article
AION Labs Launches New Startup Leveraging Machine Learning for Molecular Glue Discovery
AION Labs, a venture studio comprising several pharmaceutical and tech companies, has announced the formation of TenAces Biosciences. The startup is developing a novel approach to discover new molecular glue therapies using machine learning. The platform is expected to facilitate the discovery and development of molecular glue therapies for enhanced targeted protein degradation. TenAces emerged from AION Labs fifth startup challenge to develop an AI platform to identify naturally occurring protein interactions leading to targeted protein degradation.
PartnersInvestment
TenAces Biosciences Team
Arnout Schepers
Founder & CEO
Founder
Tomer Sidi
Chief AI Officer
Employee Info
| Employees (range) | 1-10 |
| Exact count | 6 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.